Growth will be driven by advancements in innovative therapies, including the first DMTs, and a growing patient population.

In fluctuating Parkinson's disease (PD) patients, treatment of PD using the catechol-O-methyl transferase inhibitor entacapone with carbidopa/levodopa improves quality of life and activities of ...